Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE 9 Study of presurgical Gardasil 9 to reduce recurrence after LEEP for high-grade cervical neoplasia
2018-003507-19Phase 3Active
- Sponsor
- Azienda USL Toscana Nord Ovest
- Start
- May 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN), Cervical Cancer (CC) and human papillomavirus infection comparing Gardasil 9 presurgical vaccination with Placebo presurgical control (2 arms). Primary endpoint: Reduction in disease recurrence. Started May 2021; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)human papillomavirus infection
Beyond the preview
Go deeper on 2018-003507-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003507-19.